Where China's Top Domestic & Multinational Clinical Development Leaders Meet

After a few years of tremendous growth and the creation of many new Chinese biotechs, 2019 is proving to be the year where they seek to settle into strategies that will enable success for the long term.  Industry dynamics have shifted: VC funding is much harder to come by, competition for development talent is fierce, and the field of companies vying for a share in hot new areas such as immuno-oncology/CAR-T is over-crowded.  Where is the industry headed next and what will the impact be on drug developers in China?  

This year's program will feature a streamlined program with content split into 5 distinct sections.